Methylphenidate Extended-release Generic Name & Formulations
Legal Class
CII
General Description
Methylphenidate HCl 10mg, 20mg; ext-rel tabs.
Pharmacological Class
CNS stimulant.
How Supplied
Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL
Manufacturer
Methylphenidate Extended-release Indications
Indications
Attention deficit hyperactivity disorder.
Methylphenidate Extended-release Dosage and Administration
Adults and Children
Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.
Methylphenidate Extended-release Contraindications
Contraindications
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.
Methylphenidate Extended-release Boxed Warnings
Boxed Warning
Drug abuse and dependence.
Methylphenidate Extended-release Warnings/Precautions
Warnings/Precautions
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Methylphenidate Extended-release Pharmacokinetics
See Literature
Methylphenidate Extended-release Interactions
Interactions
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Methylphenidate Extended-release Adverse Reactions
Adverse Reactions
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.
Methylphenidate Extended-release Clinical Trials
See Literature
Methylphenidate Extended-release Note
Not Applicable
Methylphenidate Extended-release Patient Counseling
See Literature
Methylphenidate Extended-release Generic Name & Formulations
Legal Class
CII
General Description
Methylphenidate HCl 10mg, 20mg; ext-rel tabs.
Pharmacological Class
CNS stimulant.
How Supplied
Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL
Manufacturer
Methylphenidate Extended-release Indications
Indications
Narcolepsy.
Methylphenidate Extended-release Dosage and Administration
Adults and Children
Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.
Methylphenidate Extended-release Contraindications
Contraindications
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.
Methylphenidate Extended-release Boxed Warnings
Boxed Warning
Drug abuse and dependence.
Methylphenidate Extended-release Warnings/Precautions
Warnings/Precautions
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Methylphenidate Extended-release Pharmacokinetics
See Literature
Methylphenidate Extended-release Interactions
Interactions
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Methylphenidate Extended-release Adverse Reactions
Adverse Reactions
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.
Methylphenidate Extended-release Clinical Trials
See Literature
Methylphenidate Extended-release Note
Not Applicable
Methylphenidate Extended-release Patient Counseling
See Literature